Posted by AGORACOM-JC
at 9:32 AM on Tuesday, March 2nd, 2021
Announce the appointment of veteran healthcare industry executive Paul Karam as Sales and Marketing Director, Europe, Middle East & Africa
Initially, Mr. Karam will be supporting the rollout and expansion in Turkey, Saudi Arabia, The United Arab Emirates and South Africa
He will also be responsible for new ventures and partnerships across the MEA Region and developing and executing the company marketing strategy in the EMEA region.
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX), a global leader in teledermatology, is pleased to announce the appointment of veteran healthcare industry executive Paul Karam as Sales and Marketing Director, Europe, Middle East & Africa (“EMEA”), effective immediately. Mr. Karam will be reporting to the Managing Director for the EMEA region and strengthening the MedX global footprint in general and EMEA presence in particular.
Mr. Karam holds a master’s degree in Biomedical Engineering from the University of Surrey in the United Kingdom. He brings 20 plus years of experience in the health care industry, where he has held several leading roles within multinational companies covering Central and Eastern Europe, Turkey, the Middle East, Africa and Pakistan markets. He has a career history with Medtronic, Molnlycke, Stryker, and several other global companies.
“Mr. Karam’s strong experience and skills will be of high added value to our overall strategy in the region, as he helps develop the EMEA region with a specific focus on Turkey, the Middle East and African sub-regions. Mr. Karam will play an integral part in accelerating MedX’s revenue growth prospects by activating his already well-established medical device distributors network to the benefit of MedX’s skin assessment telemedicine technology in the region,” said Mr. Naman Demaghlatrous, Managing Director for EMEA.
Initially, Mr. Karam will be supporting the rollout and expansion in Turkey, Saudi Arabia, The United Arab Emirates and South Africa. He will also be responsible for new ventures and partnerships across the MEA Region and developing and executing the company marketing strategy in the EMEA region.
“We are pleased to welcome Paul to the MedX team. We are fortunate to attract a person of his calibre, and I think it speaks to the strength of our offering and the opportunity it presents in the EMEA market,” stated Michael Druhan, President of Dermatological Services & Products.
Posted by AGORACOM
at 9:20 AM on Tuesday, March 2nd, 2021
Highlights:
Rhodium (Rh) is the most valuable platinum group metal (PGM), with recent spot price highs of over $US24,000/oz Rh, nearly 18 times higher than Pt
303 Rh assay results reported for the Pine Zone of the River Valley Deposit
Highest assay result is 0.177 g/t Rh, with 9 other samples returned assays at or greater than 0.100 g/t Rh and a total of 50 samples returned assays higher than 0.050 g/t Rh
The highest Rh concentrations coincide with the highest palladium (Pd) and platinum (Pt) grades – Rh concentrations in the River Valley Deposit are equivalent to 12% of the Pt grades
Based on encouraging results from phase 1, subsequent phases of the multi-phase Rh evaluation program will take samples of PGM mineralized intervals from the Dana South and Lismer zones
The River Valley Deposit is one of North Americas largest undeveloped primary platinum-group metal projects with 2.867 Moz Palladium Equivalent (PdEq) in the Measured + Indicated classifications and 1.059 Moz Pd Eq in the Inferred classification
New Age Metals Inc. (NAM) (TSXV:NAM); (OTC:NMTLF); (FSE:P7J) (“NAM” or the “Company”) announces completion of Phase 1 of an ongoing Rh assay program on the River Valley Palladium Deposit near Sudbury, Ontario (Figure 1). Phase 1 of the Rh assay program collected 303 pulp samples from 17 mineralized intervals in 14 drill holes through the Pine Zone. The samples were selected to provide Rh data for mineralization in two cross-sections spaced 50 metres apart through the Pine Zone, located near the north end of the 16 km long River Valley Deposit (Figure 1). In addition to Rh, the samples were also assayed for gold (Au), iridium (Ir), palladium (Pd), platinum (Pt), and ruthenium (Ru). The assays were completed on 2015-2020 drill core sample pulps at the Geoscience Laboratories in Sudbury.
Posted by AGORACOM
at 8:31 AM on Tuesday, March 2nd, 2021
Conducting survey to delineate Nickel targets north of Kenbridge deposit
TDEM surveys have been used extensively and successfully to aid in identifying nickel sulphide targets
Next step is to move the Kenbridge Deposit towards a Bankable Feasibility Study
Tartisan is planning a late spring early summer drill program
Tartisan Nickel Corp. (CSE:TN)(OTC Pink:TTSRF)(FSE:A2D) (“Tartisan”, or the “Company”) is pleased to provide an update on the 100% owned Kenbridge Nickel Project in Northwestern Ontario. The Company has contracted Crone Geophysics & Exploration Ltd to complete a surface Time Domain Electromagnetic (TDEM) survey over targets identified to the north of the known Kenbridge Ni-Cu-Co Deposit. The target areas are interpreted to represent similar rock types which host the Kenbridge Deposit. TDEM surveys have been used extensively and successfully to aid in identifying nickel sulphide targets like the Kenbridge Ni-Cu-Co Deposit.
The Company recently released an Updated Mineral Resource Estimate (MRE) for the Kenbridge Nickel-Copper-Cobalt Project, Atikwa Lake Area, Northwestern Ontario (press released September 17, 2020). Tartisan Nickel Corp. subsequently announced that P&E Mining Consultants Inc. have been contracted to oversee the updating of the Preliminary Economic Assessment Technical Report (“PEA”) on the Kenbridge Project (press released February 2, 2021). The “PEA” will identify the critical next steps that Tartisan needs to take to move the Kenbridge Deposit towards a Bankable Feasibility Study including permitting, geotechnical, environmental, and geological considerations.
Mark Appleby, CEO of Tartian Nickel Corp. states; “the geophysical field crew is expected to mobilize to site in the next 2 weeks. Tartisan is planning a late spring early summer drill program on the down plunge and down dip extensions to the known deposit and will look to drill targets generated from the TDEM program”. Appleby goes on to state “Tartisan will aggressively move the Kenbridge Nickel Project forward in 2021”.
Posted by AGORACOM-JC
at 4:17 PM on Monday, March 1st, 2021
Last week we introduced you to ORTHO Regenerative Technologies, a cutting-edge med tech firm that uses its proprietary RESTORE technology platform to dramatically improve the success rate of orthopedic and sports medicine surgeries.
In layman’s terms, that means company has a wonder delivery platform that delivers biologics – drugs made from biological processes – to repair soft tissues in the human body.
Now the firm has appointed Patrick O’Donnell to its board of directors.
O’Donnell comes with significant company-building experience
He will prove crucial in putting this healthcare pioneer on-track for a NASDAQ listing
Claude LeDuc, Ortho’s CEO, breaks down the appointment:
Posted by AGORACOM-JC
at 2:35 PM on Monday, March 1st, 2021
PlantX Life Inc. (VEGA: CSE) (PLTXF: OTCQB) announces massive partnerships With Alicia Silverstone and Venus Williams. Did we mention that Russell Peters attended the AGM?
Posted by AGORACOM
at 10:02 AM on Monday, March 1st, 2021
WHY ROYAL HELIUM?
Worldwide usable Helium is in short supply as demand is increasing, making it a high-priced commodity
Royal Helium has aims to deliver a minimum of 1 trillion cubic feet (Tcf) of total inert gas into the market
Via exploration and development drilling of Helium resources in southern Saskatchewan.
Highlights:
Strategy of full-cycle inert gas capture, refining and liquefaction
Commenced 3 Well Drill Program at Climax:
Production testing of 70m of potential helium bearing intervals for CLIMAX-1
Production testing of 68m of intervals for CLIMAX-2
Currently drilling CLIMAX-3
Royal Helium will be producing: helium, nitrogen and some CO2
Saskatchewan is one of the only places on earth with current and past production of primary Helium
Helium:
Scarce: Dwindling supply combined with growing demand
Helium prices have been rising due to a shortage of supply
Technical Partners:
Saskatchewan Research Council (“SRC”): Conducting engineering and scoping study for a large-scale industrial gas polygeneration facility located in Saskatchewan with RHC
AXIOM Group: Specialize in Energy Services, Geomatics, Exploration, Environment
SPROULE Associates Ltd: consulting on the completions and testing programs and to prepare an independent evaluation of the prospective helium resource from the first three wells at Climax, in accordance with the classification, definitions and guidelines of NI 51-101.
Helium Uses:
Helium
Helium is a non-substitutable and non-renewable commodity needed in many high-tech and health care industries, with specific applications in rocket engines, semiconductors, electronics, and health care.
As these sectors continue to expand, the demand for helium expands in concert.
High value and increasing Helium price
Large and growing demand Decreasing supply
Non-substitutable
Royal Helium
Strategy of full-cycle inert gas capture, refining and liquefaction
Commenced 3 Well Drill Program at Climax:
Production testing of 70m for CLIMAX-1
Production testing of 68m for CLIMAX-2
Drill rig mobilizing to drill CLIMAX-3
Mobile, membrane separation facilities: First stage of production
2nd Stage: permanent membrane separation facility
3rd Stage: Permanent poly-generation facility that makes products from the CO2 and the N2 gases
3rd or 4th stage: liquefaction facilities allowing full downstream transportation and worldwide export.
Sell products both direct to customer and wholesale to re-sellers
Largest Helium Lease Holders in N. America
4,000 square km of prospective helium lands across southern Saskatchewan
572 sections of land in Saskatchewan
Southern Saskatchewan
Saskatchewan has a history of current and historic primary helium production. It is one of the few places on the planet where helium is produced with nitrogen rather than hydrocarbons. Saskatchewan has the potential to replace supply that is leaving the market
▪High helium concentrations
▪Stable regulatory environment
▪Geopolitically favorable especially associated with production and export of critical commodities
▪Existing infrastructure, information and personnel from a long history of oil and gas exploration and production
CLIMAX & BENGOUGH HELIUM PROJECTS
Royal Helium’s initial focus begins in two areas, Climax and Bengough, identified using a combination of seismic data, well logs and aeromagnetic surveys that narrowed down prospective areas to locate the source rocks for the helium enrichment (where the helium could be trapped and accumulated)
Royal Helium’s goal is to prove-up to 30 structures, targeting between 1.0 to 2.0 Tcf (Trillion cubic feet) of raw inert gas grading at least 1% Helium
Single well costs around CAD$1.5 million with pay back in less than 1 year
Exploration Parcel #1 – CLIMAX
Royal Helium Ltd.’s Climax-1 helium exploration well drilled to target depth of 2,600m
Royal Helium Ltd. has successfully drilled Climax-2 to a total depth of 2,611m
Selected target completion intervals for both the Climax-1 and Climax-2 helium exploration wells. (potential helium-bearing zones)
The Climax-3 drilling nearing target depth
Completion and testing of Climax-1 and Climax-2 involves the sequential perforation and production testing of approximately 70 metres of potential helium-bearing zones at Climax-1 and approximately 68 metres of potential helium-bearing zones at Climax-2, both spanning multiple structural zones.
Consistent with Climax-1, the Climax-2 well was drilled into the Precambrian basement at the base of the Deadwood formation. The Deadwood is a sand and shale sequence that is known to produce helium in Saskatchewan. These first three wells are targeting different parts of the same large structural trap identified on the central portion of the Climax land block.
The seven drill targets at Climax were identified in late 2019 after the company first reprocessed 77.6 km of 2D seismic in conjunction with historic well logs and delineated a basement structure of ~3,094 hectares of four-way structural closure.
Another 17,676 hectares of helium permits (100% crown) located immediately west of its Climax property were then granted in November 2019.
To further define the possible inert gas/helium bearing formations and refine company target wells, a deep, detailed aeromagnetic survey was flown over the Climax central structure in May.
Exploration parcel #2: Bengough
South-Central Saskatchewan with Five Target Wells Comprise roughly 50% of the total land holding
Royal has reprocessed 50.36 square km of 3-D seismic, which was acquired in 2017. The re-interpretation was completed to gain an understanding of regional basement structures and to identify potential drill targets. The 3D seismic shows a large regional feature with multiple closures.
Five (5) of these closures have been identified as initial drill targets and will be subject to further detailed investigation, including an airborne magnetometer survey.
Royal believes that the Bengough basement structure is part of a larger regional basement structural trend extending at least 60 miles north from the US border and passing through three of Royal’s Focus Areas.
Along this trend, historic helium tests have ranged from 0.70% to 0.78% at Minton, 1.39% to 1.41% at Bengough, and 0.48% to 2.45% at Ogema/Ogema North.
Royals southeast Saskatchewan lands, which comprise roughly 50% of the total land holding, show the potential for robust helium occurrences. With the strategy of full-cycle inert gas capture, refining and liquefaction, it is crucial to develop a large number of derisked drill targets throughout the Company’s significant land package.
The initial five targets identified at Bengough is an exciting first step in the southeast, growing the initial target inventory to 12 when combined with the seven targets on the Climax project in southwestern Saskatchewan.
Saskatchewan Research Council
The SRC is Canada’s second-largest research and technology organization. With more than 290 employees, $91-million in annual revenue and nearly 75 years of experience, SRC provides services and products to its 1,500 clients in 27 countries around the world.
Commenced Engineering Study for a Helium Polygeneration Facility in Saskatchewan
The results of this initial engineering and economic study due Dec. 2020
Royal Helium Ltd. has initiated the engineering and scoping study for a large-scale industrial gas polygeneration facility located in Saskatchewan, which will be conducted by the Saskatchewan Research Council
The study is Royal’s first step in determining the economic potential of a large-scale facility for the separation and monetization of the gas streams associated with helium production wells in Saskatchewan.
Royal is reviewing whether there is an opportunity to monetize the complete gas stream. Current economic analysis does not include credits for other potentially commercial gases produced and processed. While the economics of helium production are significant on their own, the impact of the commercialization of other gases could substantially add to net cash flow.
Posted by AGORACOM-JC
at 10:00 AM on Monday, March 1st, 2021
Combination of Loop technologies with Maitri platform has potential to create new paradigm in $120 Billion PPE market.
Announced the signing of a letter of intent (LOI) for the grant of a non-exclusive license to Maitri Health Technologies Corp. (CSE: MTEC) for various aspects of Loop’s technology in return for CDN$2,000,000 in cash and common shares as well as a revenue-sharing arrangement.
Maitri Health Technologies is focused on modernizing healthcare systems for a post-pandemic world.
Global events in 2020 identified the need for long-term security in both healthcare and the workplace.
VANCOUVER, BC , March 1, 2021 – Loop Insights Inc. (TSXV: MTRX) (OTCQB: RACMF) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement, and automated venue tracing to the brick and mortar space, is pleased to announce the signing of a letter of intent (LOI) for the grant of a non-exclusive license to Maitri Health Technologies Corp. (CSE: MTEC) for various aspects of Loop’s technology in return for CDN$2,000,000 in cash and common shares as well as a revenue-sharing arrangement.
Maitri Health Technologies is focused on modernizing healthcare systems for a post-pandemic world. Global events in 2020 identified the need for long-term security in both healthcare and the workplace. Maitri is a global platform for healthcare supply security providing a reliable source of certified PPE (personal protective equipment) and testing solutions through an onshore manufacturing model. This model has led to the creation of innovative and industry-leading products integrated with technology to help track, trace, and enable safer workplaces and communities. Maitri’s vision for the future is for safe workplaces and institutions to enable economies to operate uninterrupted.
The global market for PPE is expected to exceed USD$123 Billion by 2027 according to Grandview Research . The global workplace safety market is expected to grow to USD$19.9 Billion by 2025 according to Research and Markets .
The combination of Loop’s technologies with Maitri’s unique products has the potential to create a comprehensive offering for PPE and technology that will provide the foundation for safer, more protected workplaces and communities.
Loop Insights CEO Rob Anson stated: “COVID-19 created an immediate need for PPE that also immediately became a highly disorganized and fragmented market of middlemen and brokers with often questionable sources. Maitri’s ability to establish secure access and trusted distribution to key PPE products through a platform positions them to quickly become a strong force in the industry. This licensing arrangement will provide the ability to add venue, business and building protection to their offering, leading to brand new opportunities and revenue models.”
LICENSING ARRANGEMENT TO COMBINE PPE, ARTIFICIAL INTELLIGENCE AND PROPTECH IN FIRST-EVER AND FULLY SCALABLE OFFERING
Maitri’s PPE line of products combined with Loop Insights technology represents the convergence of a powerful PPE, AI, and Proptech offering that enables operators, businesses and building owners to reopen and protect all constituents with a documented process from verified PPE to venue management and artificial intelligence-driven marketing opportunities. This combined protocol enables physical buildings to fully reopen, generate revenue, and remain viable assets under end-to-end protection.
As a result, Loop Insights gains access to another major industry component that is essential to the safe re-opening of the global economy and society.
“Our relationship with Loop technology will create the opportunity to deliver a more complete safety protocol along with our existing products and offerings,” said Andrew Morton , CEO of Maitri. “We’re well-positioned to play a significant role supporting a path to global economic recovery.”
TERMS OF THE LOI
Loop will license the following technology:
AI Data Insights Portal;
SmarTap Check-in Technology; and
Digital Wallet Pass Technology.
In exchange for the license, Loop will receive a total value of $2,000,000 in a combination of both:
Cash $250,000 ;
Common Shares $1,750,000 ; and
Revenue Share (terms to be determined)
Both parties have agreed to a 30-day closing period for a definitive agreement, the terms of which are subject to the approval by the Board of Directors of both companies.
Maitri Health Technologies Corp. (CSE: MTEC, FRA: D84) is a global platform for healthcare supply security. Our mission is to enhance safety and quality of life, and keep organizations and economies running. Maitri provides a reliable source of innovative, certified personal protective equipment and testing solutions through an onshore manufacturing model. Our stable, scalable supply chain is integrated with unique digital technology to deliver a comprehensive healthcare supply platform. For more information: https://maitrihealth.ca/ or [email protected]
About Loop Insights
Loop Insights Inc. is a Vancouver -based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing, and contactless solutions to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada , the US, the UK, Latin America , Australia , Japan , and Indonesia . Loop’s products and services are backed by Amazon’s Partner Network.
Tags: AI, Amazon, artificial intelligence, Big data, Bitcoin, covid19 Posted in Loop Insights Inc. | Comments Off on Loop Insights $MTRX $RACMF Signs Letter of Intent for $2,000,000 Licensing Deal with Maitri Health Technologies to Combine #PPE, Artificial Intelligence and #Proptech In First-Ever Globally Scalable Offering $AT.ca $QTRH.ca $SNSR $BSQR $PTS.ca
Posted by AGORACOM-JC
at 9:50 AM on Monday, March 1st, 2021
Liquid Avatar name and symbol change better reflects Company’s corporate branding
Announced that it has changed its name from KABN Systems NA Holdings Corp. to Liquid Avatar Technologies Inc. (www.liquidavatartechnologies.com) and its ticker symbol from KABN to LQID
TORONTO, ON / March 1, 2021 /KABN Systems NA Holdings Corp. (CSE:KABN)(“KABN” or the “Company“) is pleased to announce that it has changed its name from KABN Systems NA Holdings Corp. to Liquid Avatar Technologies Inc. (www.liquidavatartechnologies.com) and its ticker symbol from KABN to LQID. Subject to approval by the Canadian Securities Exchange (the “CSE”), the Company expects the name and symbol change to take effect for trading purposes on March 3, 2021 when its common shares will begin trading on the CSE under the new name, CUSIP number and new ticker symbol.
On February 18, 2021, the Company launched the first phase of its flagship product, the Liquid Avatar (www.liquidavatar.com) app in the Apple Store and Google Play.
Like search, online communications and browser usage, digital identity is addressable to up to 100% of the online market and is a very early-stage market opportunity, with the potential to reach up to 400 Million people in North America and over 5 Billion people online globally.
According to Statista.com, over 79% of video game users in the US are over the age of 18 with a surprising 41% over the age of 34, showing that video gaming and character creation is widespread through all age categories. Using Liquid Avatar, users are able to select from 1000’s of combinations of facial features to create their perfect digital, “cartoon-like” representations of themselves – all at no cost. Future releases of Liquid Avatar will allow users to upload their own digital icon images and create even more realistic versions of themselves as the Company explores new technologies that allow 3D animation and facial embedding on video characters.
Posted by AGORACOM
at 9:23 AM on Monday, March 1st, 2021
Mountain Valley MD Holdings Inc. (the “Company” or “MVMD“) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce it is commencing husbandry animal trials with a third-party preclinical contract research organization (“CRO”) to validate the superiority of the Company’s injectable solubilized Ivermectin technology, Ivectosol™ 1%, versus current commercially available forms to treat a broad category of animal parasites.
MVMD’s Ivectosol 1% will be tested in swine and poultry by way of advanced intra-muscular needleless injection to prove superior pharmacokinetics in terms of CMAX (peak serum concentration that a drug achieves) and AUC (area under the curve) with targeted drug withdrawal times within 10 days of administration. Additionally, the study is anticipated to demonstrate superior ease of administration with elimination of typically heavy restraint requirements, elimination of injection pain for the animal, while dramatically reducing the risk of potentially fatal clostridial infection common with traditional injection site penetration from large gauge needles.
“This is a very significant project that will move very quickly and will form the basis for our submissions in new animal drug applications to the Food and Drug Administration,” stated Dennis Hancock, President and CEO of Mountain Valley MD. “With our solubilized Ivectosol™1% solution, we will be able to pursue new injectable markets for Ivermectin such as game and poultry that doesn’t exist today, opening up tens-of-billions of animal applications globally per year.”
The Company’s Ivectosol 1% solution uses no harmful organic solvents and is the viscosity of water, which enables novel needleless injector applications. The Company believes the use of needle-free injection systems with a solubilized Ivermectin will deliver significant benefits to livestock and poultry producers, including increased efficacy and elimination of needles that transfer disease and risk of breaking into food supply, improved administration simplicity with reduced labour and safer handling protocols, minimized tissue damage that traditionally negatively impacts yields, and precision dosing that helps to eliminate human error.
Proceeding with the animal trial is part of the Company’s plan to pursue the broad husbandry and companion animal markets with its Ivectosol™ 1% technology, focused immediately on cattle, swine and poultry industries with a combined annual consumption market size of more than 67 billion animals.
Additionally, the Company is pleased to announce the introduction of Michel Rondeau, Doctor of Veterinary Medicine, as an advisor who will be overseeing the study and driving global pharmaceutical husbandry applications as part of the ongoing business commercialization of MVMD’s technology.
Dr. Rondeau has extensive experience in veterinary research having worked with numerous pharmaceutical companies in animal drug field trials and is credited with co-inventing a global award winning sprayable vaccination device that was acquired by Rhone Poulenc. Dr. Rondeau has completed an extensive range of research and development projects across a diverse range of husbandry animals including porcine industrial medicine across preventative and curative medicine, nutrition and animal health products and automated feed systems.
Posted by AGORACOM-JC
at 8:29 AM on Monday, March 1st, 2021
$1.29 million in fiscal second quarter revenue
Clinics see continued surge in demand for mental health services
Ongoing expansion of clinic capacity
TORONTO, ON / March 1, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF) (“Novamind” or “the Company”), a leading mental health company specialized in psychedelic medicine, today reported its fiscal second quarter results for the three months ended December 31, 2020 (“Fiscal Q2 2021″). The Company’s fiscal year-end is June 30th. All results are reported under International Financial Reporting Standards (“IFRS”) and in Canadian dollars, unless otherwise specified.
Fiscal Q2 2021 Highlights and Subsequent Developments
Financing and Public Listing
Novamind successfully closed an oversubscribed $10,000,000 financing on November 23rd, 2020. The funds were made available to the Company upon the completion of its reverse takeover (“RTO”) transaction and conditional listing approval from the Canadian Securities Exchange (“CSE”). The company ended the quarter with a cash balance of $10,868,742. With its strong cash position, Novamind is well-positioned to execute on its growth strategy to expand its network of mental health clinics, retreats and clinical research sites.
On January 5th, 2021, Novamind began trading on the CSE under the stock symbol “NM”. Less than two months after going public on the CSE, Novamind achieved the milestone of being included in the underlying index of the Horizons Psychedelic Stock Index ETF (NEO: PSYK) through a “Fast Entry” category, further increasing its profile with retail and institutional investors in the psychedelic medicine sector.
The Company announced on February 19th, 2021, that its common shares commenced trading under the symbol “NVMDF” on the OTC Market. In the near future, Novamind intends to apply to list its common shares on the OTCQB Market, an established marketplace in the United States for promising, innovative companies.
Operational Highlights
On January 28th, 2021, Novamind announced that it had reached two significant milestones at its Cedar Psychiatry mental health clinics: administering over 5,000 ketamine treatments since its opening in 2016, and administering over 2,000 Spravato™ treatments since the product became available in 2019. These milestones position Novamind as one of North America’s top providers of ketamine-assisted psychotherapy and Spravato™.
On January 13th, 2021, the Company announced the expansion and optimization of its Layton, Utah clinic. The redesigned Layton Clinic now offers improved treatment rooms to accommodate a higher number of ketamine and Spravato™ treatments. The Layton Clinic expansion comes in response to a significant increase in demand for ketamine therapies across Novamind’s mental health clinics. In 2020 alone, the Cedar Psychiatry clinic network facilitated over 20,000 client visits, an increase of over 100 percent compared to the same period in 2019.
On January 19th, 2021, Novamind announced the expansion of its leadership team with the appointment of Pierre Bou-Mansour, P.Eng., to the role of Chief Operating Officer. Mr. Bou-Mansour assumes the responsibility for ensuring operational excellence as Novamind develops its network of clinics, retreats, and research sites. An accomplished senior executive and leader, he brings a wealth of experience managing large and complex healthcare organizations. Prior to joining Novamind, Pierre served as the Chief Operating Officer of LifeLabs, a diagnostic laboratory services company he helped to scale into an industry leader with 5,700 employees and 370 patient access sites in Canada. Most recently, he served as the Chief Laboratory Operations Officer of Public Health Ontario, serving Canada’s largest province with over 14 million residents. In this role, Bou-Mansour successfully led the expansion of Public Health Ontario’s testing capacity for the COVID-19 response.
Strategic Investment in Bionomics
On February 11th, 2021, the Company announced that it had made a strategic investment of AU$827,486 (approximately CAN$810,000), in Bionomics Limited (“Bionomics”) (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders. In addition, Cedar Clinical Research, a wholly owned subsidiary of Novamind, will be evaluated by Bionomics as a clinical research site to conduct Bionomics’ phase IIb clinical trial examining BNC210, a drug that has received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of post-traumatic stress disorder (PTSD).
Impact of COVID-19
Novamind has not been significantly affected by the COVID-19 pandemic. As reported across multiple media outlets, the COVID-19 pandemic has resulted in a significant increase in the incidence of mental health problems, in particular anxiety and depression, conditions that are commonly treated by Novamind. The Company’s Cedar Psychiatry network of clinics continues to experience steady demand for mental health services, and this demand is anticipated to continue despite COVID-related restrictions.
Financial Highlights and Selected Consolidated Financial Information
In Fiscal Q2 2021, Novamind reported revenue of $1,288,828 primarily composed of patient services revenue from its network of four Cedar Psychiatry outpatient mental health clinics in Utah. This represents a 47 percent increase over the previous quarter ended September 30th, 2020.
The Company reported a net loss of $3,567,883 for the three months ended December 31st, 2020, as compared to a net loss of $493,614 for the prior quarter ended September 30th, 2020. The net loss for the second fiscal quarter was primarily due to expenses related to the Company’s listing on the CSE, and funding of capacity expansion at its Cedar Psychiatry clinics. This includes consulting expenses of $416,268, professional fees of $450,419, salaries and wages of $791,078, office and general expenses of $87,368, advertising and promotion expenses of $236,650, and stock-based compensation of $664,814. Additionally, there was $1,379,144 in RTO transaction costs in the quarter.
The following table presents selected financial information from the Company’s unaudited condensed interim financial statements for the three and six months ended December 31st, 2020, and periods ended December 31st, 2019.
The following information should be read in conjunction with the financial statements and management’s discussion and analysis, which are available under the Company’s SEDAR profile at www.sedar.com.
About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.
